Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease
Status:
Completed
Trial end date:
2014-01-29
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to compare the effect of migalastat (123 milligrams
[mg] of migalastat [equivalent to 150 mg of migalastat hydrochloride]) (migalastat) versus
placebo on kidney globotriaosylceramide (GL-3).